We accelerated the drug-discovery process with a high-performance digital pipeline for candidate generation, screening, and synthesis planning.
We built a high-performance discovery pipeline that generated and evaluated drug candidates before they ever reached a lab bench. The system screened compounds for stability, binding behavior, and synthesis feasibility using large-scale simulation and machine learning, which reduced unnecessary wet-lab work and helped researchers focus on the most promising candidates faster. The result was a more efficient AI for drug discovery pipeline, moving from computational exploration to real scientific decision-making.
We've built scientific computing systems that help research teams move faster with less guesswork, combining machine learning, simulation, and data pipeline design into practical tools for biotech discovery.
- High Performance Computing (HPC)
- Molecular Dynamics Simulations
- Machine Learning
- AlphaFold
- Ligand Binding Models
- Chemical Synthesis ML Models
- Stochastic and Probabilistic Modeling
- Parallel Computing
- Python
- TensorFlow
- PyTorch
- Medicine
- Pharmacology
- Confidential Pharmaceutical Client
Challenge
The client needed a faster and more efficient digital drug discovery workflow that could generate, screen, and optimize compounds while reducing computational waste. The system also needed to incorporate current machine learning and computational chemistry methods for ligand binding prediction and synthetic pathway analysis.
Solution
Dreamers built an HPC pipeline for rational drug design that used fragment libraries to generate large candidate pools, screened compounds for lipophilicity and metabolic stability, ran large-scale parallel simulations for energy and RMSD minimization, and incorporated AlphaFold-style architecture into ligand-binding models. The stack also included an ML-driven synthesis layer that suggested promising synthetic pathways from thousands of chemical heuristics.
Result
The final platform enabled highly targeted receptor agonist generation for in silico assays, reducing dependence on costly in vitro and in vivo testing. The client gained a more efficient discovery process with better precision, lower cost, and a stronger computational foundation for scientific decision-making.
"The problem of designing drugs is essentially the problem of approximating the solution to Schrodinger's equation for energy in 3D space. It's not a simple task, and they delivered a lot of value to our team of experts."